CTVA · 10-Q · 2026Q4 · Full report

Operating Expense Trends

Corteva, Inc. · 2026-11-12 · Importance 54 · Surprise 40 · No source text

R&D expense rose 13% to $397 million in the third quarter of 2026 from $351 million, and increased to $1,126 million for the first nine months from $1,061 million. The R&D increase supported long-term investment plans and reflected higher salaries, contract labor, outside contract research, field, laboratory, and facilities costs, plus unfavorable currency impacts, partly offset by third-party cost recoveries. Nine-month SG&A increased to $2,773 million from $2,632 million, driven by currency, personnel, information technology, legal support, and consulting costs.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
operating_incomenegativerealized-5.7%Corteva’s nine-month SG&A was $2,773 million, or 20% of net sales, in 2026 versus $2,632 million, or 20%, in 2025; increases included…
marginnegativerealized-2.0%Corteva’s third-quarter SG&A was $732 million, or 30% of net sales, in 2026 versus $725 million, or 28%, in 2025; increases in personnel,…
operating_incomenegativerealized-0.3%Corteva’s third-quarter SG&A was $732 million, or 30% of net sales, in 2026 versus $725 million, or 28%, in 2025; increases in personnel,…